Regeneron Pharmaceuticals, Inc.

NasdaqGS:REGN Rapport sur les actions

Capitalisation boursière : US$90.8b

Regeneron Pharmaceuticals Gestion

Gestion contrôle des critères 4/4

Regeneron Pharmaceuticals' CEO is Leonard Schleifer, appointed in Jan 1988, has a tenure of 36.83 years. total yearly compensation is $8.18M, comprised of 22.9% salary and 77.1% bonuses, including company stock and options. directly owns 2.22% of the company’s shares, worth $2.01B. The average tenure of the management team and the board of directors is 7.2 years and 17.9 years respectively.

Informations clés

Leonard Schleifer

Directeur général

US$8.2m

Rémunération totale

Pourcentage du salaire du PDG22.9%
Durée du mandat du directeur général36.8yrs
Propriété du PDG2.2%
Durée moyenne d'occupation des postes de direction7.2yrs
Durée moyenne du mandat des membres du conseil d'administration17.9yrs

Mises à jour récentes de la gestion

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why

Jun 08
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why

Recent updates

Regeneron: Buying A Promising Pipeline At A Fair Price (Rating Upgrade)

Nov 04

Amgen Biosimilar And EYLEA Patent Dispute: What It Means For Regeneron Investors

Sep 25

Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?

Sep 09
Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?

Regeneron Stock: Valuation Now Demands More Growth

Aug 26

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 81% Above Its Share Price

Aug 22
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 81% Above Its Share Price

Risks To Shareholder Returns Are Elevated At These Prices For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Aug 04
Risks To Shareholder Returns Are Elevated At These Prices For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Regeneron's Robust Pipeline And Financial Health Signal Continued Growth

Aug 02

Regeneron: Downgrading My Outlook To 'Hold' Ahead Of Q2 Earnings

Jul 11

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why

Jun 08
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

May 21
These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks

May 06

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Popularity With Investors Is Under Threat From Overpricing

Apr 30
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Popularity With Investors Is Under Threat From Overpricing

Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?

Apr 10
Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?

Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate

Mar 26

Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings

Feb 16
Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings

Regeneron Pharmaceuticals: Time To Change My Strategy After Encouraging Q4 2024

Feb 10

Regeneron's Push Into Obesity, Q4 2023 Earnings Review

Feb 02

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

Jan 31
These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

Analyse de la rémunération des PDG

Comment la rémunération de Leonard Schleifer a-t-elle évolué par rapport aux bénéfices de Regeneron Pharmaceuticals?
DateRémunération totaleSalaireBénéfices de l'entreprise
Sep 30 2024n/an/a

US$5b

Jun 30 2024n/an/a

US$4b

Mar 31 2024n/an/a

US$4b

Dec 31 2023US$8mUS$2m

US$4b

Sep 30 2023n/an/a

US$4b

Jun 30 2023n/an/a

US$4b

Mar 31 2023n/an/a

US$4b

Dec 31 2022US$7mUS$2m

US$4b

Sep 30 2022n/an/a

US$5b

Jun 30 2022n/an/a

US$6b

Mar 31 2022n/an/a

US$8b

Dec 31 2021US$6mUS$2m

US$8b

Sep 30 2021n/an/a

US$7b

Jun 30 2021n/an/a

US$6b

Mar 31 2021n/an/a

US$4b

Dec 31 2020US$135mUS$1m

US$4b

Sep 30 2020n/an/a

US$3b

Jun 30 2020n/an/a

US$3b

Mar 31 2020n/an/a

US$2b

Dec 31 2019US$21mUS$1m

US$2b

Sep 30 2019n/an/a

US$2b

Jun 30 2019n/an/a

US$2b

Mar 31 2019n/an/a

US$2b

Dec 31 2018US$27mUS$1m

US$2b

Sep 30 2018n/an/a

US$2b

Jun 30 2018n/an/a

US$2b

Mar 31 2018n/an/a

US$1b

Dec 31 2017US$27mUS$1m

US$1b

Rémunération vs marché: Leonard's total compensation ($USD8.18M) is below average for companies of similar size in the US market ($USD12.87M).

Rémunération et revenus: Leonard's compensation has been consistent with company performance over the past year.


PDG

Leonard Schleifer (71 yo)

36.8yrs

Titularisation

US$8,184,338

Compensation

Dr. Leonard S. Schleifer, M.D., Ph D., Co-founded Regeneron Pharmaceuticals, Inc. in 1988 and has been its President and Chief Executive Officer since 1988 and is its Board Co-Chair since June 2023. He ser...


Équipe de direction

NomPositionTitularisationCompensationPropriété
Leonard Schleifer
Co-Founder36.8yrsUS$8.18m2.22%
$ 2.0b
George Yancopoulos
Co-Founder23.8yrsUS$7.76m1.07%
$ 970.1m
Andrew Murphy
Executive Vice President of Research5.8yrsUS$8.43m0.049%
$ 44.3m
Daniel Van Plew
Executive VP and GM of Industrial Operations & Product Supply16.6yrsUS$8.76m0.031%
$ 28.5m
Christopher Fenimore
Senior VP of Finance & CFOless than a yearpas de données0.017%
$ 15.8m
Patrice Gilooly
Senior Vice President of Quality Assurance & Operations4.8yrspas de donnéespas de données
Bob McCowan
Senior VP of IT & Chief Information Officer3.8yrspas de donnéespas de données
Ryan Crowe
Senior Vice President of Investor Relations & Strategic Analysisno datapas de donnéespas de données
Joseph LaRosa
Executive VP13.2yrsUS$7.13m0.035%
$ 32.2m
Melissa Lozner
Senior VP & Chief Compliance Officer1.8yrspas de donnéespas de données
Christina Chan
Senior Vice President of Corporate Affairsno datapas de donnéespas de données
Sally Paull
Executive Vice President of Human Resources8.6yrspas de donnéespas de données

7.2yrs

Durée moyenne de l'emploi

64.5yo

Âge moyen

Gestion expérimentée: REGN's management team is seasoned and experienced (7.2 years average tenure).


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Leonard Schleifer
Co-Founder36.8yrsUS$8.18m2.22%
$ 2.0b
George Yancopoulos
Co-Founder23.8yrsUS$7.76m1.07%
$ 970.1m
Christine Poon
Lead Independent Director14yrsUS$748.01k0.00073%
$ 662.6k
Arthur Ryan
Independent Director21.8yrsUS$724.99k0.016%
$ 14.8m
Michael Brown
Independent Director33.4yrsUS$728.99k0.012%
$ 10.5m
Joseph Goldstein
Independent Director33.4yrsUS$709.99k0.0046%
$ 4.2m
George Sing
Independent Director36.8yrsUS$724.99k0.026%
$ 23.9m
N. Coles
Independent Director7.8yrsUS$704.99k0.000010%
$ 9.1k
Craig Thompson
Independent Director2.1yrsUS$247.79k0%
$ 0
Huda Zoghbi
Independent Director8.2yrsUS$714.99k0%
$ 0
Bonnie Bassler
Independent Director8.2yrsUS$709.99k0.0013%
$ 1.2m
Kathryn Guarini
Independent Director1.2yrsUS$1.03m0%
$ 0

17.9yrs

Durée moyenne de l'emploi

71yo

Âge moyen

Conseil d'administration expérimenté: REGN's board of directors are seasoned and experienced ( 17.9 years average tenure).